News: Announcement

President Trump’s proposal to slash public investments in the fight against global threats such as malaria, Ebola and AIDS would imperil programs that generate thousands of jobs in the United States, as they deliver breakthrough innovations that are saving millions of lives around the world, according to a new report issued today from the Global Health Technologies Coalition (GHTC). “From 2007 to 2015 alone, $14 billion in US investments in global health innovations advanced numerous new technologies for fighting many dangerous diseases while attracting substantial private sector commitments and creating 200,000 new American jobs,” said GHTC Director Jamie Bay Nishi. “It’s hard to imagine many other investments of taxpayer dollars that have provided such impressive returns.” Return on innovation: Why global health R&D is a smart investment for the United States is a collaboration between GHTC and the health-oriented think tank Policy Cures Research. It examines the broad impact of US spending on global health R&D at a time when the Trump administration is proposing big cuts in programs that rank among the most successful US-sponsored global health and medical research initiatives ever undertaken. According to the report, since 2000, US investments across multiple agencies have played a pivotal role in building partnerships with industry and philanthropy that have delivered 42 new products that are contributing to big wins for global health. They include new malaria drugs designed especially for children, which are credited with saving 750,000 lives, and an inexpensive meningitis vaccine that, costing a mere 50 cents per dose, already has prevented 378,000 deaths—and is on track to save $9 billion in treatment costs by 2020. US support also has proved instrumental in the development of two new medicines to fight drug-resistant tuberculosis, the world’s most advanced malaria vaccine, and a low-cost vaccine targeting a strain of rotavirus, a potentially deadly diarrheal disease, that is common among children in India. Meanwhile, US investments have helped move 128 promising new global health tools into late-stage development, including a new vaccine candidate against Ebola, a new HIV vaccine candidate, and the first vaginal microbicide ring that has been shown to reduce a woman’s risk of contracting HIV. Moreover, while the spending is directed at global health challenges, the report finds that the innovations it helps produce are largely home-grown American products. The analysis reveals that most of the money—about 89 cents of every government dollar—stays in the US, where it funds US researchers and stimulates significant industry investments as well. For example, the report notes that in 2015 alone, the US government provided $192 million to support global health product development at US-based pharmaceutical and biotech companies. The companies responded with $294 million of additional investments. Overall, the report finds that between 2007 and 2015, public investments in global health R&D generated $33 billion in economic output. “The public investment is critical because most of the victims of diseases like meningitis and malaria are too poor to offer the kind of commercial market incentives that attract industry interest,” said Nishi. “But we have found many pharmaceutical and biotech companies are willing to turn their considerable talents to developing global health technologies if they have a reliable partner willing to share the risk.” Already inconsistent, public funding for global health research faces new perils Despite the strong returns on taxpayer investments, federal spending on global health R&D has been unreliable. The report reveals that in 2015, putting aside the one-time emergency allocation for Ebola response, public investments in global health R&D were a quarter of a billion dollars below 2012 levels. Amid an already declining trend in US global health R&D funding, now President Trump is proposing significant further cuts across the government’s global health and medical research portfolio. They include a 23 percent cut for the National Institute of Health’s National Institute of Allergy and Infectious Diseases (NIAID), which funds critical research on emerging infectious diseases like Zika, along with existing threats like HIV/AIDS, malaria and tuberculosis; and the elimination of the Fogarty International Center, which builds partnerships and trains researchers around the world. The President also has proposed a 25 percent overall cut to global health programs at the US Agency for International Development (USAID) and State Department, including a 49 percent cut to global health security at USAID and zeroing of USAID’s HIV/AIDS account, which funds vital research for new HIV prevention technologies. The Centers for Disease Control and Prevention (CDC) would see a 20 percent cut in funding for global health programs, which would include a steep reduction in support for polio and other critical immunization initiatives along with cuts to disease surveillance activities that provide vital sentinels for detecting emerging threats that could reach the US. The risk gap grows: Global threats rise as R&D investments fall The report notes the potential costs of cutting support for research focused on developing technologies that could prove decisive in addressing or even stopping the next global health emergency. The study points out that prior to the Ebola outbreak of 2014, investments by US and Canadian governments had produced a promising vaccine candidate—but then it was “shelved due to a lack of ongoing funding,” which meant it was not ready to deploy during the crisis. The report notes that its availability during the outbreak could have saved many lives, in addition to billions of dollars spent on emergency response. Meanwhile, the report offers examples of how global health R&D can be a form of domestic preparedness, a point that has been punctuated by the recent arrival of Zika in the US and the steady, if stealthier, incursion of lesser known threats, as well. For example, a parasitic infection called Chagas disease, which can start with fever and vomiting and then progress to chronic heart and intestinal complications, is increasingly found in the US. Once confined mainly to Latin America, the report notes that Chagas now infects up to 300,000 people in the US and generates an estimated $900 million annually in health care costs and productivity losses. Experts note that the Chagas burden in the US is now approaching better-known diseases, like Lyme. “It’s alarming to see such uncertainty around funding for global health research at a time when risks are on the rise,” said Nishi. “Global health threats tend to first emerge in the poorest corners of the world, and that’s where we should be fighting them—before they reach American shores. And as this report shows, in addition to saving lives, investing in such efforts has a positive effect on both the US economy and US preparedness." ### About the Global Health Technologies Coalition The Global Health Technologies Coalition (GHTC) works to save and improve lives by encouraging the research and development of essential health technologies. We are a coalition of more than 25 nonprofit organizations advancing policies to accelerate the creation of new drugs, vaccines, diagnostics, and other health tools that bring health lives within reach for all people. GHTC is housed at PATH. About Policy Cures Research Policy Cures Research is a non-profit, global health think tank, based in Sydney, Australia. It aims to provide research, information, decision-making tools and strategic analysis to help governments, funders, researchers and civil society organizations with the information they need to make optimal R&D policy and funding decisions for global health.

Today, 33 leading global health organisations and members of national parliaments have issued an open letter to G20 heads of state, calling for them to increase the prioritization of health by the G20, and establish the G20 as a permanent global health policy forum. The letter calls for heads of state to continue the strong focus on research and development (R&D) to address critical challenges like emerging and drug-resistant infectious diseases. The signatories also encourage G20 leaders to include the conclusions of the inaugural Health Minister’s declaration in next week’s declaration of the G20 Heads of State Communique in Hamburg. Given the growing risk to humanity the letter urges leaders to increase financial and political support for global health R&D, and to encourage private sector and philanthropic organisations to accelerate addressing anti-microbial resistance, pandemic preparedness and poverty related neglected diseases.   “I fully endorse the G20 Leaders’ decision to place Global Health Innovation on the G20 agenda. We must prioritise AMR R&D in key pathogens –such as HIV, TB, Malaria, and NTDs–moving forward.”– Jeremy Lefroy MP, UK Member of Parliament, Chair of the Parliamentary Network on the World Bank and International Monetary Fund “The G20 gives developing countries more power and coordination in managing the global economy. We welcome their decision to place Global Health Innovation and critical issues like antimicrobial resistance in malaria, TB and HIV on the agenda. In doing so, the G20 is making a powerful statement that they intend to address the full range of issues that affect world economies – a critical step forward for global health and wealth.” – David Reddy, CEO MMV   “At a time when global health challenges—like antimicrobial resistance and emerging infectious diseases—are on the rise, it is critical that G20 nations join together to make sure we have the vaccines, medicines, and other tools in hand to address current as well as future health crises.”– Jamie Bay Nishi, Director, Global Health Technologies Coalition “The medical technology industry is committed to the fight against AMR, which is a global public health issue in need of global leadership. MedTech Europe would welcome G20 support in the uptake of medical technologies that have a great potential to prevent the misuse and overuse of antibiotics throughout the patient pathway.” – MedTech Europe Chancellor Angela Merkel has put global health at the heart of her government’s G20 Presidency. This momentum must be built on, with the G20 becoming a permanent forum for ministerial dialogue and action on global health policy, starting with next year’s Argentinian presidency. ### Notes to Editor:   Further information about Global Health Innovation Event: The “Research for Impact and the G20: How can global health innovation drive sustainable development?” roundtable event, held on Friday, April 28th 2017, at the Quadriga Forum in Berlin, Germany was organized by Sovereign Strategy and co-hosted with the following organizations: the Global Alliance for TB Drug Development (TB Alliance), Medicines for Malaria Venture (MMV), the Sabin Vaccine Institute, the Coalition for Epidemic Preparedness Innovations (CEPI), PATH (Program for Appropriate Technology in Health), the Global Health Technologies Coalition (GHTC), the Global Health Innovative Technology (GHIT) Fund, UNITAID, and CARB-X. The one-day roundtable event involved opening and closing speeches, two sessions of moderated roundtable discussions, presentations on the G20 priority foci of Antimicrobial Resistance (AMR) and pandemic preparedness, the B20 and its health initiative as well as the current project, its “Call to Action” (CTA) output document, and discussions on how to carry it forward. The stated objective was to create a platform for cooperation and policy advocacy for an open and unique coalition of organizations following the declaration of the G20 Health Ministers and leading up to the G20 Hamburg Summit. The roundtable discussions are summarized in the Rapporteur’s Report. Over 100 public and private health stakeholders backed four recommendations agreed the roundtable in a “Call to Action”, published ahead of the G20 Health Ministers summit.